Tag: AstraZeneca

AstraZeneca is a British–Swedish multinational pharmaceutical and biopharmaceutical company. In 2013 it moved its headquarters to Cambridge, England, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015 it was the eighth largest drug company in the world based on sales revenue.

Russia is one of the key markets for the company “AstraZeneca”. In October 2015 in the Kaluga region took place the grand opening of the company’s plant in Russia. Total investment in the creation of the company was $224 million. In addition, “AstraZeneca” is one of the largest companies that invest in scientific and research activities. In Russia, company conducts clinical research, which today includes more than six thousand patients. Seven and a half thousand patients participating in company studies, clinical practice. In 2016 company expanded scientific cooperation with Russian Society of Clinical Oncology and continued partnership with “Skolkovo” biomedcluster.

Lynparza Approved for gBRCAm Metastatic Pancreatic Adenocarcinoma Treatment

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that Lynparza (olaparib) has been approved in the US for the maintenance treatme...

FDA Recommended Lynparza for Metastatic Adenocarcinoma of Pancreas Treatment

AstraZeneca and MSD Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee ...

AstraZeneca Received Marketing Authorisation from NMPA for Imfinzi

china street
AstraZeneca announced that it has received marketing authorisation from China’s National Medical Products Administration (NMPA) for Imfinzi (durvalumab) for the treatment of patients with unrese...

AZ and Daiichi Sankyo Presented “Clinically Meaningful” Responses to Trastuzumab Deruxtecan

AstraZeneca and Daiichi Sankyo have presented new mid-stage data showing “clinically meaningful” responses in patients with advanced breast cancer taking trastuzumab deruxtecan. The pivotal Phase I...

AstraZeneca and Novoheart will Develop First Functional Model of Specific Type of Heart Failure

AstraZeneca has announced a collaboration with biotechnology company Novoheart to develop the world’s first functional model of a specific type of heart failure. The companies will work together to...

AstraZeneca Agreed to Sell Rights to Seroquel and Seroquel XR in the US and Canada

AstraZeneca has agreed to sell the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in the US and Canada to Cheplapharm Arzn...

FDA Accepted sBLA and Granted Priority Review for Imfinzi

astrazeneca
AstraZeneca announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for Imfinzi (durvalumab) for the treat...

Jerusalem Venture Partners and AstraZeneca Signed Cooperation Agreement

astrazeneca
Jerusalem Venture Partners and British multinational pharmaceutical company AstraZeneca have signed a cooperation agreement to identify, develop and invest in digital health in Israel, the Jerusalem-b...

FDA Approved New Treatment Option for Patients with Chronic Lymphocytic Leukemia

As part of Project Orbis, a collaboration with the Australian Therapeutic Goods Administration (TGA) and Health Canada, the U.S. Food and Drug Administration granted supplemental approval to Calquence...

European Commission Approved AstraZeneca Qtrilmet

diabetes
AstraZeneca announced that the European Commission has approved Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) modified-release tablets to improve glycaemic control in adults with t...

FDA Accepted NDA and Granted Priority Review for Selumetinib

astrazeneca
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that the US Food and Drug Administration (FDA) has accepted a New Drug Applicati...

Analyses of Roxadustat Showed No Increased CV Risk in CKD-Associated Anaemia

astrazeneca
AstraZeneca and partner FibroGen presented a cardiovascular (CV) safety readout at the American Society of Nephrology (ASN) conference from pooled analyses of the HIF-PH inhibitor roxadustat, also kno...

AstraZeneca Presented Detailed Results from Phase III Trials of Roxadustat

astrazeneca
AstraZeneca presented detailed results from the Phase III OLYMPUS and ROCKIES trials showing that roxadustat significantly increased haemoglobin (Hb) levels in non-dialysis-dependent (NDD) and dialysi...

Sun Pharmaceutical Announced Licensing Agreement with AstraZeneca

sun pharma
Sun Pharmaceutical Industries Ltd. announced that it has entered into a licensing agreement with AstraZeneca UK Ltd. (AstraZeneca) to introduce certain novel ready to-use (RTU) infusion oncology produ...

AstraZeneca Launches Large-Scale Initiatives in China for Global Medicine R&D Advancement

astrazeneca
AstraZeneca announced three large-scale initiatives to build on the Company’s long-standing commitment to China and advance global research and development (R&D) for innovative new medicines. T...

AstraZeneca to Sell Rights to Seroquel and Seroquel XR in Europe and Russia

astrazeneca
AstraZeneca has agreed on the sale and license of the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia ...